Antitumor Activity

• Potent cytotoxicity across multiple solid tumor models
• Activity retained in drug-resistant cancer cell lines
• Significant tumor growth inhibition in:
  • Xenograft models
  • Transgenic mouse models
• Normal tissues spared, supporting a favorable therapeutic index

Pharmacokinetics & Distribution

• IV administration
• Rat half-life: ~2 hours
• Large volume of distribution (Vss ~65 L/kg)
• PK profile supports once-weekly dosing

Pharmacodynamics

Clear PD evidence consistent with mitochondrial stress:

• AMPK activation
• Inhibition of mTOR/S6K signaling
• Induction of a “cellular starvation” biomarker signature